| 000 | 02568 a2200697 4500 | ||
|---|---|---|---|
| 005 | 20250513123129.0 | ||
| 264 | 0 | _c19970825 | |
| 008 | 199708s 0 0 eng d | ||
| 022 | _a0006-4971 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDibenedetto, S P | |
| 245 | 0 | 0 |
_aDetectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. _h[electronic resource] |
| 260 |
_bBlood _cAug 1997 |
||
| 300 |
_a1226-32 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aAsparaginase _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 |
_aBlotting, Southern _xmethods |
| 650 | 0 | 4 |
_aBone Marrow _xpathology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xanalysis |
| 650 | 0 | 4 |
_aDaunorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aEvaluation Studies as Topic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorometry |
| 650 | 0 | 4 | _aGene Rearrangement, delta-Chain T-Cell Antigen Receptor |
| 650 | 0 | 4 | _aGene Rearrangement, gamma-Chain T-Cell Antigen Receptor |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aItaly _xepidemiology |
| 650 | 0 | 4 |
_aLeucovorin _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia-Lymphoma, Adult T-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMercaptopurine _xadministration & dosage |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 |
_aNeoplastic Stem Cells _xchemistry |
| 650 | 0 | 4 |
_aNucleic Acid Hybridization _xmethods |
| 650 | 0 | 4 |
_aPolymerase Chain Reaction _xmethods |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aReceptors, Antigen, T-Cell, gamma-delta _xanalysis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aLo Nigro, L | |
| 700 | 1 | _aMayer, S P | |
| 700 | 1 | _aRovera, G | |
| 700 | 1 | _aSchilirò, G | |
| 773 | 0 |
_tBlood _gvol. 90 _gno. 3 _gp. 1226-32 |
|
| 999 |
_c9222521 _d9222521 |
||